潜在可手术非小细胞肺癌纵隔转移预测模型及EBUS-TBNA检测的前瞻性研究
该前瞻性研究在589例潜在可手术的非小细胞肺癌(NSCLC)患者中开发了纵隔转移预测模型(PLUS-M)和EBUS-TBNA检测纵隔转移预测模型(PLUS-E),并在309例回顾性队列中验证。开发队列纵隔转移患病率为35.3%,EBUS-TBNA灵敏度为87.0%。两模型在开发和验证队列中均显示出良好的区分度和校准度。
要点
- PLUS-M和PLUS-E可用于NSCLC纵隔转移及EBUS-TBNA检测的预测。
- 开发队列纵隔转移患病率35.3%,EBUS-TBNA灵敏度87.0%。
- 两模型在验证队列中AUC分别为0.859和0.900,校准良好。
核心结论
- PLUS-M和PLUS-E可有效用于NSCLC有创纵隔分期的决策。
研究设计与样本
- 前瞻性开发队列纳入589例潜在可手术NSCLC患者,来自韩国五家教学医院(2016年7月至2019年6月)。
- 采用多变量逻辑回归开发PLUS-M和PLUS-E模型。
- 使用不同时期的回顾性队列(n=309,2019年6月至2021年8月)进行验证。
主要发现
- 开发队列中,经EBUS-TBNA或手术诊断的纵隔转移患病率为35.3%,EBUS-TBNA灵敏度为87.0%。
- PLUS-M中,较年轻年龄(<60岁和60-70岁相比≥70岁)、非鳞状组织学(腺癌和其他)、中央型肿瘤位置、肿瘤大小(>3-5 cm)、CT分期cN1或cN2-3、PET-CT分期cN1或cN2-3是N2-3疾病的显著危险因素。
- 开发队列中PLUS-M的AUC为0.876(95%CI 0.845-0.906),PLUS-E的AUC为0.889(95%CI 0.859-0.918)。
临床怎么用
- PLUS-M和PLUS-E可用于辅助决定NSCLC患者是否需要进行有创纵隔分期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prediction models for mediastinal metastasis and its detection by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) have not been developed using a prospective cohort of potentially operable patients with non-small cell lung cancer (NSCLC). RESEARCH QUESTION: Can mediastinal metastasis and its detection by EBUS-TBNA be predicted with prediction models in NSCLC? STUDY DESIGN AND METHODS: For the prospective development cohort, 589 potentially operable patients with NSCLC were evaluated (July 2016-June 2019) from five Korean teaching hospitals. Mediastinal staging was performed using EBUS-TBNA (with or without the transesophageal approach). Surgery was performed for patients without clinical N (cN) 2-3 disease by endoscopic staging. The prediction model for lung cancer staging-mediastinal metastasis (PLUS-M) and a model for mediastinal metastasis detection by EBUS-TBNA (PLUS-E) were developed using multivariable logistic regression analyses. Validation was performed using a retrospective cohort (n = 309) from a different period (June 2019-August 2021). RESULTS: The prevalence of mediastinal metastasis diagnosed by EBUS-TBNA or surgery and the sensitivity of EBUS-TBNA in the development cohort were 35.3% and 87.0%, respectively. In PLUS-M, younger age (< 60 years and 60-70 years compared with ≥ 70 years), nonsquamous histology (adenocarcinoma and others), central tumor location, tumor size (> 3-5 cm), cN1 or cN2-3 stage by CT, and cN1 or cN2-3 stage by PET-CT were significant risk factors for N2-3 disease. Areas under the receiver operating characteristic curve (AUCs) for PLUS-M and PLUS-E were 0.876 (95% CI, 0.845-0.906) and 0.889 (95% CI, 0.859-0.918), respectively. Model fit was good (PLUS-M: Hosmer-Lemeshow P = .658, Brier score = 0.129; PLUS-E: Hosmer-Lemeshow P = .569, Brier score = 0.118). In the validation cohort, PLUS-M (AUC, 0.859 [95% CI, 0.817-0.902], Hosmer-Lemeshow P = .609, Brier score = 0.144) and PLUS-E (AUC, 0.900 [95% CI, 0.865-0.936], Hosmer-Lemeshow P = .361, Brier score = 0.112) showed good discrimination ability and calibration. INTERPRETATION: PLUS-M and PLUS-E can be used effectively for decision-making for invasive mediastinal staging in NSCLC. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02991924; URL: www. CLINICALTRIALS: gov.
引用
- Chung HS, Yoon HI, Hwangbo B, et al. Prediction Models for Mediastinal Metastasis and Its Detection by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Potentially Operable Non-Small Cell Lung Cancer: A Prospective Study. Chest. 2023. PMID: 37019355. doi:10.1016/j.chest.2023.03.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。